Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
77 hedge funds and large institutions have $140M invested in Marinus Pharmaceuticals, Inc in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 8 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
23% more call options, than puts
Call options by funds: $8.31M | Put options by funds: $6.77M
1% more capital invested
Capital invested by funds: $139M → $140M (+$1.06M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 81 → 77 (-4)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.35M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.28M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.03M |
| 4 |
BlackRock
New York
|
+$998K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$811K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.37M |
| 2 |
Jennison Associates
New York
|
-$1.22M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$883K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$809K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$460K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
76
Spark Investment Management
New York
| – | -$208K | -12,475 | Closed |
|
|
OAM
77
Oxford Asset Management
Oxford,
United Kingdom
| – | -$183K | -10,929 | Closed |
|
78
Acadian Asset Management
Boston,
Massachusetts
| – | -$98K | -5,872 | Closed |
|
79
AQR Capital Management
Greenwich,
Connecticut
| – | -$79K | -4,712 | Closed |
|
|
RFC
80
Regions Financial Corp
Birmingham,
Alabama
| – | -$17K | -1,021 | Closed |
|
|
CHP
81
Cable Hill Partners
Portland,
Oregon
| – | -$17K | -1,000 | Closed |
|
|
LTFS
82
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$17K | -1,000 | Closed |
|
|
AG
83
Advisor Group
Phoenix,
Arizona
| – | +$226 | +13 | New |
|
MRNS Hedge Fund Activity: Q2 2019 in Review
77 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2019, worth a combined $140M — up 0.76% from $139M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MRNS and 7 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 29 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.35M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $1.37M sold.
- 77 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2019, down from 81 in Q1 2019.
- Funds reported $140M of Marinus Pharmaceuticals, Inc stock for Q2 2019, up 0.76% quarter-over-quarter.
- 7 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2019 and 8 closed out, a net change of -1 holder.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2019 was Alyeska Investment Group, an estimated $4.35M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2019 was Tekla Capital Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2019.